MedTrace Logo

Study on AUNIP as a Novel Tumor Marker for Cervical Cancer

NCT06118463 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-11-09

No results posted yet for this study

Summary

To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic and prognostic value.

Conditions

Interventions

DIAGNOSTIC_TEST

Detection of serum AUNIP expression

The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.

Sponsors & Collaborators

  • Lin Yuan

    lead OTHER

Principal Investigators

  • Lin Yuan, Ph.D. · Qianfoshan Hospital

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2027-10-01
Completion
2029-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06118463 on ClinicalTrials.gov